PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 18, 2026SLAS TECHNOLOGY2 citationsOpen Access

Integrative Single-Cell and Bulk Transcriptomics Analysis Reveals Cellular Heterogeneity, Immune Microenvironment Dynamics, and Prognostic Signatures in Oral Squamous Cell Carcinoma

View Full Paper
MZMin ZhangChina Pharmaceutical UniversityHWHaicheng WangShanghai Stomatological HospitalDZDawei ZhangChinese University of Hong Kong

Key Points

  • The aim is to explore the molecular complexity of oral squamous cell carcinoma (OSCC) to develop targeted therapies.
  • Combined single-cell RNA sequencing and bulk transcriptomics to analyze OSCC samples.
  • Used dimensionality reduction, trajectory inference, cell-cell communication analysis, and spatial transcriptomics.
  • Conducted survival analysis with Kaplan-Meier methods and assessed pathway enrichment with GSEA.
  • Identified distinct molecular subtypes of OSCC linked to differential survival outcomes (p < 0.001).
  • Single-cell profiling revealed 6-8 major cell clusters with significant cellular heterogeneity.
  • Established a six-gene prognostic signature that stratified patients into high-risk and low-risk groups.

Abstract

BACKGROUND: Oral squamous cell carcinoma (OSCC) represents a significant global health burden with heterogeneous clinical outcomes. Understanding the molecular and cellular complexity of OSCC is crucial for developing precision therapeutic strategies. METHODS: We performed comprehensive integrative analysis combining single-cell RNA sequencing (scRNA-seq) and bulk transcriptomics to characterize the cellular landscape of OSCC. Samples from HPV-positive, HPV-negative, recurrent, and non-recurrent cases were analyzed using advanced computational approaches including dimensionality reduction, trajectory inference, cell-cell communication analysis, and spatial transcriptomics. Survival analysis was performed using Kaplan-Meier methods, and pathway enrichment was assessed using GSEA. Immunotherapy response predictors were evaluated based on PD-L1 expression, tumor mutational burden, and immune cell infiltration patterns. RESULTS: Our analysis identified distinct molecular subtypes of OSCC with differential survival outcomes (p < 0.001). Single-cell profiling revealed significant cellular heterogeneity with 6-8 major cell clusters including cancer epithelial cells, cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), T cells, and B cells. Epithelial-mesenchymal transition (EMT) pathway showed significant enrichment (NES = 2.5, pFDR = 0.001) in aggressive tumor subtypes. Trajectory analysis identified branching developmental paths from pre-malignant states through dysplasia to invasive carcinoma and recurrent disease. Cell-cell communication networks revealed extensive interactions between immune cells, fibroblasts, and cancer cells through key ligand-receptor pairs including VEGF-VEGFR2, EGF-EGFR, and Collagen-CD44 (p = 0.00001). Spatial transcriptomics analysis demonstrated distinct tumor microenvironmental niches with specific cellular compositions. Methylation analysis revealed strong negative correlation with gene expression (R = -0.70, p < 0.001), indicating epigenetic regulation. A six-gene prognostic signature effectively stratified patients into high-risk and low-risk groups. Immunotherapy response prediction identified PD-L1 expression (likelihood score 0.75) and tumor mutational burden as key biomarkers. Cell type proportions significantly correlated with recurrence rates (R² = 0.65, p < 0.001). CONCLUSIONS: This comprehensive multi-omics analysis provides unprecedented insights into OSCC cellular heterogeneity, tumor microenvironment dynamics, and disease progression mechanisms. Our findings identify novel prognostic biomarkers and therapeutic targets, particularly highlighting the potential of immunotherapy in specific patient subsets. The integrated single-cell and spatial transcriptomics approach offers a framework for precision medicine in oral cancer management.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a0aac6d5ba8ef6d83b6fd67https://doi.org/10.1016/j.slast.2026.100432
Ask AI
Helpful
Bookmark
Share
View Full Paper